KR20230038526A - 혈장 칼리크레인 억제제 - Google Patents

혈장 칼리크레인 억제제 Download PDF

Info

Publication number
KR20230038526A
KR20230038526A KR1020237004707A KR20237004707A KR20230038526A KR 20230038526 A KR20230038526 A KR 20230038526A KR 1020237004707 A KR1020237004707 A KR 1020237004707A KR 20237004707 A KR20237004707 A KR 20237004707A KR 20230038526 A KR20230038526 A KR 20230038526A
Authority
KR
South Korea
Prior art keywords
mmol
mixture
chloro
stirred
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237004707A
Other languages
English (en)
Korean (ko)
Inventor
재클린 디. 힉스
롱제 쿠앙
크리스토퍼 제이. 신즈
메튜 제이. 롬바르도
호반 알렉산더 로페즈
로한 머첸트
필립 패트릭 샤프
지카이 우
지키앙 자오
알란 씨. 챙
송 양
지안밍 바오
마오쿤 티안
갈렌 폴 쉬안-낸스
Original Assignee
머크 샤프 앤드 돔 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 엘엘씨 filed Critical 머크 샤프 앤드 돔 엘엘씨
Publication of KR20230038526A publication Critical patent/KR20230038526A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237004707A 2020-07-10 2021-07-06 혈장 칼리크레인 억제제 Withdrawn KR20230038526A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063050220P 2020-07-10 2020-07-10
US63/050,220 2020-07-10
PCT/US2021/040420 WO2022010828A1 (en) 2020-07-10 2021-07-06 Plasma kallikrein inhibitors

Publications (1)

Publication Number Publication Date
KR20230038526A true KR20230038526A (ko) 2023-03-20

Family

ID=79552050

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237004707A Withdrawn KR20230038526A (ko) 2020-07-10 2021-07-06 혈장 칼리크레인 억제제

Country Status (9)

Country Link
US (1) US12528786B2 (cg-RX-API-DMAC7.html)
EP (1) EP4178620B1 (cg-RX-API-DMAC7.html)
JP (1) JP7773522B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230038526A (cg-RX-API-DMAC7.html)
CN (1) CN116157154B (cg-RX-API-DMAC7.html)
AU (1) AU2021306250A1 (cg-RX-API-DMAC7.html)
CA (1) CA3185597A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000507A (cg-RX-API-DMAC7.html)
WO (1) WO2022010828A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4210694B1 (en) * 2020-09-10 2025-10-15 Merck Sharp & Dohme LLC Plasma kallikrein inhibitors
WO2024173196A1 (en) * 2023-02-17 2024-08-22 Merck Sharp & Dohme Llc Plasma kallikrein inhibitors
WO2026096331A1 (en) * 2024-10-30 2026-05-07 Merck Sharp & Dohme Llc Plasma kallikrein inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609866B2 (en) 2009-12-18 2013-12-17 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
HRP20221373T1 (hr) 2014-03-07 2023-01-06 Biocryst Pharmaceuticals, Inc. Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
KR102286305B1 (ko) 2014-07-16 2021-08-09 라이프에스씨아이 파마슈티컬스, 인크. 치료적 억제 화합물
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
WO2017001926A2 (en) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc Therapeutic inhibitory compounds
WO2017072020A1 (en) * 2015-10-27 2017-05-04 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
US10640486B2 (en) * 2015-10-27 2020-05-05 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
BR112018008506B8 (pt) 2015-10-29 2023-12-05 Merck Sharp & Dohme Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos
EP3612523B1 (en) 2017-04-21 2021-06-09 Boehringer Ingelheim International GmbH Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
GB201719882D0 (en) * 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
CN113039181B (zh) * 2018-08-16 2024-08-13 勃林格殷格翰国际有限公司 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物
KR102931248B1 (ko) * 2020-06-16 2026-03-03 머크 샤프 앤드 돔 엘엘씨 혈장 칼리크레인 억제제

Also Published As

Publication number Publication date
CN116157154A (zh) 2023-05-23
US12528786B2 (en) 2026-01-20
WO2022010828A1 (en) 2022-01-13
EP4178620A1 (en) 2023-05-17
CA3185597A1 (en) 2022-01-13
AU2021306250A1 (en) 2023-02-16
EP4178620A4 (en) 2024-08-07
JP7773522B2 (ja) 2025-11-19
CN116157154B (zh) 2026-05-01
US20230348428A1 (en) 2023-11-02
EP4178620B1 (en) 2026-04-01
JP2023533519A (ja) 2023-08-03
MX2023000507A (es) 2023-02-09

Similar Documents

Publication Publication Date Title
EP3134408B1 (en) FACTOR XIa INHIBITORS
JP7787890B2 (ja) 血漿カリクレイン阻害剤
WO2016018701A1 (en) FACTOR XIa INHIBITORS
EP4178620B1 (en) Plasma kallikrein inhibitors
EP4210694B1 (en) Plasma kallikrein inhibitors
KR102931248B1 (ko) 혈장 칼리크레인 억제제
JP7794991B2 (ja) 血漿カリクレイン阻害薬
WO2024173196A1 (en) Plasma kallikrein inhibitors
EP4308125B1 (en) Plasma kallikrein inhibitors
RU2849957C1 (ru) Ингибиторы калликреина плазмы
EP4326274B1 (en) Plasma kallikrein inhibitors
RU2852935C1 (ru) Ингибиторы калликреина плазмы
RU2854493C2 (ru) Ингибиторы калликреина плазмы
RU2844952C1 (ru) Ингибиторы калликреина плазмы
WO2026096331A1 (en) Plasma kallikrein inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202